Gender differences in liver cancer risk explained by small changes in genome

January 19, 2012
When mice are exposed to a liver carcinogen, normally male mice develop many tumors, while female mice are protected (left part of the figure). However, in mice lacking the Foxa genes, the situation is reversed (right part of the figure). Thus, the Foxa genes are essential determinants of the sexual dimorphism in liver cancer risk. Credit: Klaus Kaestner, PhD, Perelman School of Medicine, University of Pennsylvania; Cell

Men are four times more likely to develop liver cancer compared to women, a difference attributed to the sex hormones androgen and estrogen. Although this gender difference has been known for a long time, the molecular mechanisms by which estrogens prevent -- and androgens promote -- liver cancer remain unclear.

Now, new research, published in Cell this week from the lab of Klaus Kaestner, PhD, professor of Genetics in the Perelman School of Medicine at the University of Pennsylvania, has found that the difference depends on which proteins the bind next to. Specifically a group of transcriptional regulatory proteins called Foxa 1 and 2.

Normally, when mice are given a liver carcinogen, male mice develop many tumors while females get very few. Strikingly, this gender-related incidence of was completely reversed in mice genetically engineered by the team to lack the Foxa genes after the team induced cancer. Using complex genomic analyses, the researchers could show that the actions of both estrogens and androgens in the liver are Foxa dependent, explaining the reversal in cancer risk.

But how does this translate to human liver cancer when there are 5,000 places in the where Foxa factors can bind? The team looked for genetic markers called SNPs that intersect with Foxa protein binding. A SNP is a DNA sequence variation occurring when a single nucleotide, or DNA building block, differs between members of a biological species or paired chromosomes in an individual. Knowing that in women the estrogen receptor protects against liver cancer, they looked for SNP markers within Foxa binding sites in tissue samples from women with and without liver cancer.

Strikingly, women with liver cancer frequently had within specific Foxa binding sites. The researchers then showed that the mutated SNP acts not only to abolish binding of the Foxa proteins, but also of the estrogen receptor to its target sites nearby. This impairment of estrogen receptor binding is thought to result in loss of the protective effect of estrogens, and increased liver . Future research will have to determine if the same holds true in reverse in men. In addition, if the human data are validated in larger cohorts of patients, this research might lead to tests for predicting the genetic risk of liver cancer.

Explore further: Genetic variant linked to development of liver cancer in hepatitis C virus carriers

Related Stories

Cholesterol contributes to bone loss during aging

September 28, 2011

(Medical Xpress) -- High cholesterol has been found to contribute to a loss of bone density in two ways, according to researchers at Duke University Medical Center. It blocks formation of new bone cells and it encourages ...

Elevated hormone levels add up to increased breast cancer risk

October 21, 2011

Post-menopausal women with high levels of hormones such as estrogen or testosterone are known to have a higher risk of breast cancer. New research published in BioMed Central's open access journal Breast Cancer Research looked ...

Recommended for you

New role for an old protein: Cancer causer

September 3, 2015

A protein known to play a role in transporting the molecular contents of normal cells into and out of various intracellular compartments can also turn such cells cancerous by stimulating a key growth-control pathway.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.